Results 171 to 180 of about 94,347 (282)

A Multiple‐Model‐Informed Drug‐Development Approach for Optimal Regimen Selection of an Oncolytic Virus in Combination With Pembrolizumab

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 572-582, March 2025.
ABSTRACT The antitumor efficacy of an intratumoral injection of a genetically engineered oncolytic vaccinia virus carrying human IL‐7 and murine IL‐12 genes (hIL‐7/mIL‐12‐VV) was demonstrated in CT26.WT‐bearing mice. In the CT26.WT‐bearing mouse model, the efficacy of the combination of hIL‐7/mIL‐12‐VV plus the anti‐programmed cell death protein (PD)‐1
Akihiro Yamada, Mary P. Choules, Frances A. Brightman, Shigeru Takeshita, Shinsuke Nakao, Nobuaki Amino, Takeshi Nakayama, Masato Takeuchi, Kanji Komatsu, Fernando Ortega, Hitesh Mistry, David Orrell, Christophe Chassagnole, Peter L. Bonate   +13 more
wiley   +1 more source

Recent progress in cadonilimab research for oncology applications. [PDF]

Front Immunol
Dong MZ, Cui M, Zhu EB, Lin MQ, Dong GH, Jin GL, Qu LZ, Che HY, Guan HJ.   +8 more
europepmc   +1 more source

T‐Cell Immunity and Lung Cancer

Respirology, EarlyView.
ABSTRACT Lung cancer remains a leading cause of cancer mortality worldwide. Although immune checkpoint inhibitors (ICIs) have reshaped therapeutic strategies in lung cancer, their benefits remain limited. ICIs exert their therapeutic efficacy by activating T‐cell effector functions, underscoring the central role of T cells in antitumor immunity.
Kotaro Yamada, Yosuke Togashi
wiley   +1 more source

CTLA4 genetic variants influence immune regulation and susceptibility of HPV associated cervical cancer. [PDF]

Discov Oncol
de Oliveira MC, Fortunato GM, da Silva PR, Pacheco BLB, da Silva MR, Brajão de Oliveira K.   +5 more
europepmc   +1 more source

Nanomedicine Meets Immunotherapy: Transforming Chimeric Antigen Receptor T Cell Treatment for Solid Tumors

Small Science, EarlyView.
This review highlights recent advances in nanomedicine that enhance chimeric antigen receptor (CAR) T cell therapy against solid tumors. It discusses key barriers to CAR T cell efficacy and outlines nanotechnology‐based strategies to improve tumor targeting, remodel the immunosuppressive microenvironment, and integrate nanomaterials into CAR T cell ...
Stephen O’Rourke, Nuo Xu, Hongjun Wang, Hexin Chen   +3 more
wiley   +1 more source

ROSE12, a novel anti-CTLA-4 FcγRs binding-enhanced antibody activated by extracellular adenosine triphosphate, shows tumor-selective regulatory T-cell depletion and antitumor efficacy without systemic immune activation. [PDF]

J Immunother Cancer
Hayashi H, Tatsumi K, Katada H, Matsuda Y, Tsunenari T, Honda M, Nemoto T, Shimizu S, Miura-Okuda M, Ikuta Y, Ito A, Ogami C, Kato C, Kamimura M, Kibayashi T, Kubo C, Komatsu S, Komori Y, Shinozuka J, Susumu H, Tanno H, Tomii Y, Nakagawa K, Nagano H, Nanami M, Nishito Y, Fujisawa N, Matsushita T, Michisaka S, Yamazaki M, Yoshimoto M, Wakatsuki H, Wakabayashi T, Wada NA, Ueda O, Konishi H, Kashima K, Tanaka H, Endo M, Kitazawa T, Sakaguchi S, Kamata-Sakurai M, Igawa T.   +42 more
europepmc   +1 more source

Identification of genetically predicted protein biomarkers and drug targets for prostate cancer via Mendelian randomization

VIEW, EarlyView.
Prostate cancer, a leading cause of cancer in men globally, urgently requires improved diagnostic and treatment strategies. This study analyzed large genetic datasets and identified five key proteins (THBD, DST, IFI27L2, OSBPL10, PPP1R14A) that either increase or decrease cancer risk, while also exploring their roles in immune response and potential ...
Maoping Cai, Tianming Peng, Zhiyue Xie, Chuqian Zhen, Chen Yao, Nan Peng, Qianyi Li, Yuzhong Yu, Jiming Bao, Xian‐Lu Song, Mingkun Chen, Shan‐Chao Zhao   +11 more
wiley   +1 more source

Retrospective analysis of cutaneous immune-related adverse events following checkpoint inhibitor therapy in melanoma patients reveals increased risk associated with the HLA-B*51:01 allele. [PDF]

Cancer
DiLeo M, Oglesby S, Leung CH, Pauken KE, Farooq S, Haydu LE, Kubicki SL, Martinez R, Welborn M, Zahiruddin S, Zou J, Cao K, Patel AB.   +12 more
europepmc   +1 more source

Cytotoxic T lymphocyte antigen-4 (CTLA-4) als therapeutisches Target in der Tumorimmuntherapie [PDF]

Arzneimittelforschung, 2012
openaire   +1 more source

Personalized Cancer Vaccines in the Clinical Trial Pipeline

Asia-Pacific Journal of Clinical Oncology, EarlyView.
This study analyzes the current landscape of personalized cancer vaccine clinical trials, highlighting trends in vaccine platforms, trial phases, and geographic distribution. Peptide and dendritic cell vaccines dominate early‐stage research, with promising immune responses observed in melanoma, glioblastoma, and urothelial cancer trials.
Liudmila Iamukova, Elena Alferova
wiley   +1 more source